Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Medicare Part D Prior Auth Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Prior Authorization Requirements — Part D prior authorization and coverage criteria

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Rules governing prior authorization, coverage criteria, exclusions, and required documentation for multiple Part D drugs on the HealthPartners Part D formulary effective March 1, 2026; applies to Medicare Part D claims under HealthPartners.

    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part D prior authorization and coverage criteria (multiple Part D drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis and required supporting documentation (e.g., genetic testing, hemodynamics, labs) per product-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    03/01/2026formulary effective date shown
    All FDA-approvedmany products limited to FDA-approved indications
    12 monthstypical coverage duration
    >=150eosinophil threshold (Dupixent/NUCALA)
    4/momigraine initiation threshold

    Coverage Criteria (Initial & Renewal — product-specific)

    Patient selection: patient must not have an FDA‑labeled limitation of use or contraindication to therapy. This is a universal exclusion applicable to requests across the product entries in this section and will result in denial when present. Providers must document the FDA‑approved diagnosis and any required test results or genetic testing where specified (e.g., abiraterone genotype guidance or other product‑specific testing) to demonstrate the request meets initial authorization requirements. (See product‑specific entries for required prior therapy, diagnostic confirmation, dosing limits, and coverage duration.)

    Actemra (tocilizumab) authorization: Actemra may not be used concurrently with other biologic therapies. Initial approval requires documentation of a labeled indication (examples: rheumatoid arthritis with inadequate response to at least two preferred agents, polyarticular JIA after failure of two preferred drugs, giant cell arteritis after failure of one preferred agent, systemic sclerosis‑associated ILD after inadequate response to mycophenolate). Requests should include prior therapy history and prescriber specialty or consultation (rheumatologist or pulmonologist). Coverage is typically authorized for 12 months and dosing is limited to FDA‑labeled ranges.

    Adbry (tralokinumab) coverage requirements: Adbry may not be used concurrently with another monoclonal antibody therapy. Initial authorization for atopic dermatitis requires documentation of moderate‑to‑severe disease (for example ≥10% body surface area or involvement of critical sites), evidence of intractable symptoms (pruritus, oozing/cracking/bleeding), and failure or contraindication to at least one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor. Prescriber specialty (allergist, immunologist, or dermatologist) and objective prior‑therapy documentation are required; dosing must follow FDA labeling and typical approvals are for 12 months.

    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part D prior authorization and coverage criteria (multiple Part D drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis and required supporting documentation (e.g., genetic testing, hemodynamics, labs) per product-specific criteria.
    SourceLink
    On This Page
    Coverage Criteria (Initial & Renewal — product-specific)Initial Therapy — Product-specific Decision NodesContinuation / Renewal CriteriaStep Therapy / Prior Therapy RequirementsQuantity Limits and Dosing ConstraintsProvider Actions — Prior Authorization, Documentation & Denial RisksCoding, Clinical Thresholds & Index ReferencesSite of Care and Part B vs Part D DeterminationsDefinitions & Diagnostic ThresholdsFormulary Index & Coding ReferencesBiosimilar / Preferred Agent NotesBackground — Scope and Policy PurposeRevision History

    Pulmonary arterial hypertension (PAH) therapies: concurrent use exclusions and diagnostic confirmation. Many PAH agents are contraindicated with nitrates, nitric oxide donors, phosphodiesterase (PDE) inhibitors, or non‑specific PDE inhibitors; requests that propose concurrent use with these agents will be denied. Initial authorization for WHO Group 1 PAH requires right heart catheterization demonstrating hemodynamics with mean pulmonary arterial pressure ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units, and prescriber must be or consult a cardiologist or pulmonologist. Renewal generally requires the patient be seen within the prior 12 months and evidence of clinical benefit; dosing is limited to FDA‑labeled ranges and coverage is typically for 12 months.

    Alpha‑1 antitrypsin augmentation: eligibility and required testing. Authorization requires a confirmed diagnosis of alpha‑1 antitrypsin deficiency with clinically evident emphysema and documentation of pretreatment AAT level below the policy threshold (for example <11 micromoles/L or the equivalent mg/dL thresholds specified by assay). Providers must also document continuation of conventional emphysema therapies. Approvals are dose‑limited to FDA labeling and usually authorized for 12 months.

    Initial Therapy — Product-specific Decision Nodes

    Continuation / Renewal Criteria

    Step Therapy / Prior Therapy Requirements

    Drug / ScenarioRequired prior trials / step therapy
    Actemra (selected indications)Medical contraindication or inadequate response to at least two preferred drugs (examples: Hadlima, Simlandi, Rinvoq) for RA or polyarticular JIA; for giant cell arteritis inadequate response to at least one preferred drug
    Actemra — systemic sclerosis‑associated ILDInadequate response to mycophenolate (medical contraindication or failure) prior to approval
    Drug class / examplePrior trial requirement
    Selected neurology and psychiatry agents (examples)Inadequate response or contraindication to two preferred/alternative agents (e.g., two antiseizure meds for certain agents) prior to approval
    Antidepressant/antipsychotic new starts (examples)Inadequate response or contraindication to two preferred alternative antidepressants or antipsychotics as listed in product-specific sections
    DrugRequired prior alternatives (examples)
    AUSTEDO (new‑start patients)Inadequate response or contraindication to two listed alternatives (examples: lurasidone, risperidone, ziprasidone, olanzapine, quetiapine, aripiprazole) prior to approval
    Drug / IndicationRequired prior agents
    BENLYSTA SC — SLE indicationInadequate response or contraindication to two of: hydroxychloroquine, immunosuppressive agents (mycophenolate, azathioprine, methotrexate, cyclophosphamide), or oral corticosteroids prior to approval
    BENLYSTA SC — lupus nephritisInadequate response or contraindication to mycophenolate mofetil or cyclophosphamide prior to approval
    Drug / IndicationRequired prior preferred drugs
    CIMZIA (certolizumab pegol) — various inflammatory indicationsMedical contraindication or inadequate response to at least two preferred drugs listed per indication (preferred lists provided per diagnosis) prior to approval
    ContextStep therapy expectation
    Biologic and specialty agents (general)Many biologic approvals require prior inadequate response or medical contraindication to multiple preferred agents; exact required agents vary by product and indication
    Enbrel / adalimumab pathway examplesDocumented failure or contraindication to at least one preferred adalimumab drug (Hadlima, Simlandi) required unless exception applies
    ScenarioRequired trial
    Lipid management prior to certain specialty lipid therapies (example: NEXLETOL/REPATHA prerequisites)Trial of one high‑intensity statin plus ezetimibe concomitantly for a minimum of 8 weeks (or documented statin intolerance) before approval when LDL remains >70 mg/dL
    Drug (requesting STELARA)Step requirement
    STELARA (ustekinumab) — patients requesting STELARAPatient must have trialed both SELARSDI and YESINTEK prior to STELARA approval (step requirement) per product-specific PA rules
    Drug / Indications (examples)Prior trial requirement
    TYENNE (selected RA / polyarticular JIA examples)Prior inadequate response or contraindication to at least two preferred agents (examples listed such as Hadlima, Simlandi, Rinvoq) required before TYENNE approval; prescriber specialty indicated
    ContextPrerequisite therapy flag / note
    Index / formulary entries and select product recordsSome product entries indicate 'Prerequisite Therapy Required: Yes' (e.g., Zurzuvae maintenance listing); prerequisite therapy may be required for some products — documented per product entry

    Quantity Limits and Dosing Constraints

    ATTRUBY — Quantity limits
    ATTRUBY quantity limitLimited to a dose within the FDA‑labeled dosing guidelines
    ScopeApplies to ATTRUBY (ATTR‑CM) product entries referencing Part D coverage
    Duration/renewal noteRenewal requires patient seen within past 12 months and demonstrated efficacy (per ATTRUBY criteria)
    BENLYSTA SUBCUTANEOUS — Quantity limits
    BENLYSTA SC quantity limitLimited to a dose within the FDA‑labeled dosing guidelines
    Concurrent therapy exclusionMay not be used concurrently with another biologic agent
    Renewal requirementRenewal requires positive response and patient seen within last 14 months
    BONSITY — Duration and limits
    BONSITY duration limitLimited to 2 years unless patient remains at or returns to high fracture risk
    Prerequisite therapyPrior inadequate response or contraindication to one other osteoporosis therapy such as bisphosphonates required
    Coverage contextApplies to FDA‑approved osteoporosis indications including glucocorticoid‑associated osteoporosis
    bosentan oral tablet — Quantity limits and constraints
    bosentan dosing limitLimited to a dose within the FDA‑labeled dosing guidelines
    PAH hemodynamics requiredRight heart catheterization showing mPAP >=20 mmHg, PCWP <=15 mmHg, PVR >2 Wood units
    Liver test limitsPatient must not have ALT/AST >3x ULN or bilirubin increase >=2x ULN
    Various listed products — Dose limits
    Various products dosing limitLimited to a dose within the FDA‑labeled dosing guidelines
    Examples includedApplies across multiple specialty biologic and non‑biologic product entries listed in the formulary extract
    Coverage durationCoverage durations vary by product (commonly 6 or 12 months) per product entry
    Various specialty drugs — Dose limits
    Specialty drugs dosing limitLimited to a dose within the FDA‑labeled dosing guidelines
    Prescriber restriction noteMany specialty drugs require prescribing by or in consultation with a specialist as specified per product
    Coverage duration noteTypical coverage duration is 12 months unless product‑specific shorter initial durations apply
    VALCHLOR — Quantity limits
    VALCHLOR quantity limitTwo 60 gram tubes per month
    Prior therapyInitial criteria include prior skin‑directed therapy (e.g., topical corticosteroids) before approval
    Renewal requirementRenewal requires lack of disease progression; typical initial coverage six months then 12 months on renewal

    Provider Actions — Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    Abiraterone — prior authorization required

    Abiraterone (250 mg or 500 mg) requires prior authorization. For new starts submit: diagnosis of an FDA‑approved indication (e.g., metastatic high‑risk castration‑sensitive or metastatic castration‑resistant prostate cancer); genetic testing results when required and evidence the agent is appropriate; confirmation patient has no FDA‑labeled limitation of use or contraindication; and if 500 mg tablet is requested provide a rationale why the 250 mg tablet cannot be used. Dose must be within FDA‑labeled dosing. Initial approval length: 6 months; renewal requires positive response.

    • Diagnosis must match an FDA‑approved indication
    • Provide genetic testing results when required
    • If requesting 500 mg tablet, explain why 250 mg tablet is not suitable
    • Dose limited to FDA‑labeled dosing; initial approval 6 months
    Prior Authorization

    Actemra — prior authorization and step requirements

    Actemra requires prior authorization. Submit documentation of a diagnosis consistent with listed indications (RA, polyarticular JIA, giant cell arteritis, systemic juvenile idiopathic arthritis, or systemic sclerosis‑associated ILD) and evidence of inadequate response or contraindication to the specified number of preferred drugs per indication. Actemra may not be used concurrently with other biologic therapies; prescriber must be or consult a rheumatologist or pulmonologist. Coverage duration: 12 months.

    • Diagnosis matching listed Actemra indications
    • Prior inadequate response or contraindication to required preferred agents
    • Do not use concurrently with other biologic therapies
    • Prescriber: rheumatologist or pulmonologist; coverage 12 months
    Prior Authorization

    Adbry — prior authorization and prerequisite therapy

    Adbry (subcutaneous) for atopic dermatitis requires prior authorization. Provide documentation of moderate‑to‑severe disease (≥10% BSA or involvement of face/neck/hands/feet/genitals/intertriginous areas) with intractable pruritus or oozing/cracking, and evidence of inadequate response or contraindication to one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor. Adbry may not be used concurrently with another monoclonal antibody; prescriber specialty required. Coverage 12 months.

    • Moderate‑to‑severe atopic dermatitis (≥10% BSA or critical site involvement)
    • Failure or contraindication to one prescription topical corticosteroid or one topical calcineurin inhibitor
    • No concurrent monoclonal antibody therapy; specialist prescriber
    • Coverage duration 12 months
    Prior Authorization

    PAH therapies — RHC confirmation and PA required

    Pulmonary arterial hypertension (PAH) therapies require prior authorization with right heart catheterization confirmation. Submit pretreatment RHC demonstrating mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units (or ≥3 WU per some entries), documentation of negative acute vasodilator response or trial/failure/contraindication to calcium channel blockers when applicable, and that prescriber is or consulted a cardiologist/pulmonologist. Many PAH agents prohibit concurrent use with nitrates, nitric oxide donors, or PDE inhibitors. Coverage typically 12 months.

    • Right heart catheterization: mean PAP ≥20 mmHg; PCWP ≤15 mmHg; PVR >2 (or ≥3) Wood units
    • Document negative acute vasodilator test or CCB trial/failure when required
    • Prescriber: cardiologist or pulmonologist; no concurrent nitrates/PDE inhibitors
    • Coverage duration 12 months
    Prior Authorization

    AIMOVIG — prior authorization and renewal limits

    AIMOVIG (CGRP antagonist) requires prior authorization for migraine prevention. Documentation must show ≥4 migraine days per month. Initial authorization is for 6 months; renewal is 12 months and requires positive response. AIMOVIG must not be used concurrently with other CGRP antagonists.

    • ≥4 migraine days per month required for initiation
    • Initial approval 6 months; renewal 12 months with documented benefit
    • Do not use concurrently with other CGRP preventive agents
    Documentation Required

    Sleep disorder agents — diagnostic documentation required

    Prior authorization for sleep/wake disorder agents requires diagnosis of an FDA‑approved indication and condition‑specific diagnostic documentation: for OSA, sleep study showing ≥15 obstructive events/hour OR ≥5 events/hour plus listed symptoms; for narcolepsy, polysomnography plus MSLT unless not feasible. Renewal requires positive response to therapy.

    • OSA: sleep study with ≥15 events/hour OR ≥5 events/hour plus symptoms
    • Narcolepsy: polysomnography plus MSLT documentation (unless not feasible)
    • Do not use concurrently with another target agent (e.g., modafinil)
    • Renewal requires positive response
    Prior Authorization

    ATTRUBY — diagnostic confirmation and PA requirements

    ATTRUBY (ATTR‑CM) prior authorization requires confirmed ATTR‑CM by cardiac biopsy with Congo red and ATTR confirmation OR specified noninvasive criteria (negative light‑chain testing plus 99mTc‑PYP myocardial uptake >1.5 H/CL ratio or visual grade ≥2). Also document heart failure history and NYHA class I–III and exclude light‑chain amyloidosis. Renewal requires prescriber visit within 12 months and evidence of continued efficacy.

    • Cardiac biopsy with Congo red and ATTR confirmation OR serum/urine immunofixation + free light chain ratio and 99mTc‑PYP uptake >1.5 or grade ≥2
    • Document HF history and NYHA I–III
    • Exclude AL (light‑chain) amyloidosis; renewal: seen within 12 months and continued efficacy
    Prior Authorization

    BENLYSTA SC — PA with lab confirmation and prior therapy

    BENLYSTA subcutaneous requires prior authorization. Provide evidence of autoantibody‑positive SLE (anti‑dsDNA >30 IU/mL, low complement, or anti‑Smith) or active lupus nephritis with required lab confirmation, and documentation of inadequate response or contraindication to specified standard therapies (e.g., hydroxychloroquine, immunosuppressants, or corticosteroids). Renewal requires positive response and a visit within the last 14 months.

    • Anti‑dsDNA >30 IU/mL or low complement or anti‑Smith for SLE
    • Inadequate response or contraindication to two listed standard therapies
    • Renewal: positive response and prescriber visit within 14 months
    • Do not use concurrently with another biologic
    Prior Authorization

    BONSITY — PA and prior therapy requirement

    BONSITY prior authorization requires diagnosis of an FDA‑approved osteoporosis indication and prior inadequate response or contraindication to another osteoporosis therapy (e.g., bisphosphonates). Coverage is limited to 2 years unless the patient remains or returns to high fracture risk.

    • Diagnosis of FDA‑approved osteoporosis indication
    • Prior inadequate response or contraindication to another therapy such as a bisphosphonate
    • Coverage limited to 2 years unless ongoing high fracture risk
    Prior Authorization

    Bosentan — PA with RHC and liver test requirements

    Bosentan (for Group 1 PAH) prior authorization requires RHC confirmation of Group 1 PAH (mPAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 WU) and baseline liver tests showing ALT/AST not >3×ULN and bilirubin increase <2×ULN. Prescriber should be or consult cardiology/pulmonology. Bosentan may not be used with cyclosporine A or glyburide.

    • RHC: mPAP ≥20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units
    • ALT/AST ≤3×ULN and bilirubin increase <2×ULN at baseline
    • Do not use concurrently with cyclosporine A or glyburide
    • Prescriber: cardiologist or pulmonologist; coverage 12 months
    Prior Authorization

    BRUKINSA — prior authorization and indication documentation

    BRUKINSA prior authorization requires documentation of the FDA‑approved hematologic diagnosis (e.g., MCL after ≥1 prior therapy; WM; CLL/SLL; relapsed MZL after anti‑CD20; relapsed FL after ≥2 lines with obinutuzumab) and that the patient has no FDA‑labeled limitation or contraindication. Coverage duration typically 6 months; renewal requires positive response.

    • Diagnosis and prior therapy documentation per indication (e.g., MCL after ≥1 prior therapy)
    • No FDA‑labeled limitation/contraindication
    • Coverage 6 months; renewal based on response
    Prior Authorization

    Cosentyx — prior authorization and step therapy

    Cosentyx requires prior authorization with diagnosis‑specific criteria (psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, non‑radiographic axial spondyloarthritis, enthesitis‑related arthritis, hidradenitis suppurativa) and documentation of inadequate response or contraindication to required prior therapies. Cosentyx may not be used concurrently with other biologic therapies; prescriber specialty and coverage 12 months.

    • Diagnosis consistent with listed indications and prior therapy failure/contraindication as specified
    • May not be used with other biologics
    • Prescriber specialty (dermatologist/rheumatologist) as applicable; coverage 12 months
    Prior Authorization

    Dupixent — PA with indication‑specific lab and prior therapy evidence

    Dupixent prior authorization requires indication‑specific documentation: for atopic dermatitis show moderate‑to‑severe disease (≥10% BSA or special‑site involvement) and failure/contraindication to one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor; for eosinophilic or steroid‑dependent asthma submit pre‑treatment eosinophil count ≥150 cells/mcL and evidence of inadequate control despite medium/high‑dose inhaled steroid plus another maintenance agent and defined exacerbation history. Dupixent may not be used concurrently with another monoclonal antibody.

    • Atopic dermatitis: ≥10% BSA or critical site involvement + failure of topical prescription steroid or topical calcineurin inhibitor
    • Asthma: pre‑treatment eosinophils ≥150 cells/mcL and inadequate control on inhaled steroid + another maintenance medication with exacerbation history
    • Do not use with another monoclonal antibody; coverage and renewal per indication
    Prior Authorization

    MAVYRET / HCV DAA — PA with RNA, interaction screening, specialist

    HCV DAA regimens (including MAVYRET) require prior authorization aligned with current AASLD/IDSA guidance. Submit diagnosis of HCV, HCV RNA within the past 6 months, medication‑interaction screening (patient must not be taking listed interacting drugs), documentation of no prior failure of an NS5A+protease inhibitor DAA regimen, and absence of moderate/severe hepatic impairment (Child‑Pugh B/C). Prescriber should be or consult GI/hepatology/ID/transplant specialist. Coverage duration per regimen (e.g., 8–16 weeks).

    • HCV RNA within 6 months and adherence to AASLD/IDSA guidance
    • Avoid listed interacting medications (e.g., carbamazepine, rifampin, certain statins, cyclosporine >100 mg/day, EPCLUSA/HARVONI/VOSEVI/ZEPATIER)
    • No prior NS5A + protease inhibitor DAA failure; no Child‑Pugh B/C
    • Specialist prescriber or consultation; coverage per guideline (8–16 weeks)
    Note
    Prior Authorization

    REVCOVI — diagnostic confirmation and PA requirements

    REVCOVI prior authorization (for ADA‑deficient SCID) requires confirmed ADA deficiency by one of the listed laboratory or genetic tests (e.g., decreased erythrocyte ATP, biallelic ADA1 mutation, absent ADA in cells/plasma, or positive TREC screening) and documentation that the patient is not a candidate for or has failed hematopoietic stem cell transplant. Initial coverage six months; renewal requires annual visit and provider attestation.

    • Laboratory/genetic confirmation of ADA deficiency (one of listed tests)
    • Documentation that HSCT is not an option or has failed
    • Initial approval six months then 12 months if renewal criteria met
    Note
    Prior Authorization

    VOWST — PA, preparatory steps, and limits

    VOWST prior authorization requires documentation of recurrent CDI defined as three or more prior episodes treated with antibiotics (e.g., vancomycin), completion of the antibiotic therapy 2–4 days before initiating VOWST, and completion of recommended magnesium citrate preparation the day before (and at least 8 hours prior) to dosing. Coverage is limited to a single treatment course of 10 days; use for non‑recurrent CDI or not meeting the recurrent definition risks denial.

    • Recurrent CDI: three or more prior antibiotic‑treated episodes
    • Completed antibiotic therapy 2–4 days prior to VOWST
    • Completed magnesium citrate prep day before and ≥8 hours prior to dosing
    • Coverage limited to single 10‑day treatment course
    Denial Risk

    VOWST — denial risk if recurrent CDI criteria or prep steps not met

    VOWST exclusion risk: requests that do not meet the policy definition of recurrent CDI (three or more prior episodes treated with antibiotics) or that request VOWST for primary CDI will be denied. Ensure documentation of the required prior episodes and completion of antibiotic and prep steps before submission.

    • VOWST is restricted to recurrent CDI (3+ prior antibiotic‑treated episodes)
    • Use for primary CDI or without required preparatory steps will be denied
    Prior Authorization

    XIFAXAN — indication‑specific PA and dose/retreatment limits

    XIFAXAN prior authorization is indication‑specific. For IBS‑D the dose is limited to 550 mg three times daily for 14 days with retreatment limited to patients with prior benefit (maximum two 14‑day courses); travelers’ diarrhea limited to 3 days; hepatic encephalopathy requires lactulose intolerance/limited dosing and routine follow‑up. Provide indication‑specific prior therapy failure or contraindication documentation per the listed rules.

    • IBS‑D: 550 mg TID for 14 days; retreatment limited and max two 14‑day courses
    • Traveler’s diarrhea: 3‑day course after failure/contraindication to listed antibiotics
    • Hepatic encephalopathy: lactulose dose limitation and prescriber follow‑up; coverage durations vary by indication
    Prior Authorization

    XOLAIR — baseline testing and PA requirements

    XOLAIR prior authorization requires baseline diagnostic/laboratory evidence per indication (e.g., allergic asthma: positive allergen testing and baseline IgE ≥30 IU/mL; chronic urticaria: inadequate response to maximally tolerated H1 antihistamine). XOLAIR may not be used concurrently with another monoclonal antibody; renewal requires evidence of positive response. Prescriber specialty required for many indications.

    • Allergic asthma: positive skin/blood allergen test + baseline IgE ≥30 IU/mL and inadequate control on inhaled steroid + another maintenance med
    • Chronic urticaria: failure of maximally tolerated H1 antihistamine
    • Do not use concurrently with another monoclonal antibody; renewal requires documented benefit
    Note

    Index cross‑references — consult formulary product pages

    Where a formulary index entry directs to a product page (e.g., Kesimpta pen, Kerendia, Kalydeco), consult the referenced formulary page for the product‑specific prior authorization, coverage, and billing details. Index cross‑references list the formulary page number to find the full PA and documentation requirements.

    • Use index page references to locate product‑specific PA criteria in the formulary
    • Index entries do not contain the full PA criteria — open the referenced page
    Note
    Note
    Note
    Note
    Note
    Note

    Coding, Clinical Thresholds & Index References

    No explicit CPT/HCPCS/ICD-10 codes providedmixed
    N/ANo explicit CPT/HCPCS/ICD-10 codes listed in this excerpt
    Products listed (no billing codes presented)mixed
    N/ADocument lists product names and criteria; no discrete CPT/HCPCS/ICD-10/NDC codes provided in these chunks.
    Formulary references / identifiersmixed
    FID: 26132HealthPartners Part D Formulary identifier
    Right heart catheterization parameters
    Mean pulmonary artery pressure (mean PAP)>= 20 mmHg
    Pulmonary capillary wedge pressure (PCWP)<= 15 mmHg
    Pulmonary vascular resistance (PVR)> 2 Wood units
    Alpha‑1 antitrypsin level thresholds
    Pretreatment serum AAT level (primary)< 11 micromoles/L
    Radial immunodiffusion equivalent< 80 mg/dL
    Nephelometry equivalent< 57 mg/dL
    Migraine frequency for preventive therapy
    Migraine frequency threshold>= 4 migraine days per month
    Initial coverage lengthInitial authorization commonly 6 months for CGRP preventive agents
    Concurrency exclusionConcurrent use with other CGRP antagonists is prohibited
    OSA sleep study thresholds
    OSA diagnostic threshold (primary)>= 15 obstructive events per hour
    Alternate OSA threshold>= 5 events/hour PLUS at least one daytime symptom (e.g., daytime sleepiness)
    Narcolepsy confirmatory testingPolysomnography plus Multiple Sleep Latency Test (MSLT)
    99mTc‑PYP myocardial uptake — diagnostic threshold
    99mTc‑PYP myocardial uptake criterion>1.5 heart‑to‑contralateral (H/CL) ratio OR visual grade >=2
    ATTR‑CM diagnostic contextUsed as part of noninvasive diagnostic criteria when cardiac biopsy not performed
    Light‑chain exclusionMust exclude light chain amyloidosis per ATTRUBY criteria
    Eosinophil threshold for Dupixent (asthma)
    Dupixent eosinophil threshold (asthma)>= 150 cells/mcL (pre‑treatment within prior 12 months)
    Dupixent asthma prerequisiteInadequate control despite medium/high‑dose inhaled steroid plus at least one other maintenance med
    Renewal evidenceRenewal requires documented positive clinical response (reduced exacerbations, improved symptoms/FEV1)
    Teriparatide maximum duration and related limits
    Teriparatide maximum duration2 years
    BONSITY exceptionBONSITY coverage limited to 2 years unless patient remains/returns to high fracture risk
    Prerequisite therapyPrior inadequate response or contraindication to another osteoporosis therapy required for anabolic agents
    GATTEX dose and prerequisites
    GATTEX dosing0.05 mg/kg per day (FDA‑approved dose)
    Parenteral nutrition prerequisitePatient must have been dependent on parenteral nutrition >=1 year and unable or not planned to taper requirements
    Renewal requirementRenewal requires positive response to therapy
    INBRIJA — age and pulmonary considerations
    INBRIJA age restriction>= 18 years
    Pulmonary function considerationProvider attestation required if FEV1 <50% (limited study data)
    Adjunct requirementPatient must be taking carbidopa/levodopa and have education on inhaler technique
    Kerendia — renal and electrolyte thresholds (UACR/eGFR/K+)
    Urine albumin-to-creatinine ratio (UACR)>= 30 mg/g
    eGFR requirement>= 25 mL/min/1.73m2
    Serum potassium requirement<= 5.0 mEq/L
    Estimated glomerular filtration rate (eGFR) and related lab limits
    Estimated glomerular filtration rate (eGFR)>= 25 mL/min/1.73m2
    Urine albumin-to-creatinine ratio (UACR)>= 30 mg/g
    Serum potassium<= 5.0 mEq/L before initiation
    Serum potassium threshold
    Serum potassium limit before therapy<= 5.0 mEq/L
    Associated requirementsRequires UACR >=30 mg/g and eGFR >=25 mL/min/1.73m2 for Kerendia initiation
    RenewalRenewal requires continued ACE/ARB use or documented contraindication and positive response
    Follow‑up visit interval for renewal
    Follow‑up visit interval for renewalPatient must have been seen within the last 12 months (where specified)
    ExamplesCommon renewal requirement across many products (e.g., Kalydeco, GATTEX, PAH agents) to document response and safety
    DocumentationProvider visit notes and objective measures often required for renewal
    Duration of prior platinum‑based chemotherapy (Lynparza)
    Lynparza platinum‑chemo duration (pancreatic maintenance)>= 16 weeks of prior platinum‑based chemotherapy
    Indication-specific requirementDuration requirement applies to maintenance pancreatic cancer indication per Lynparza criteria
    DocumentationProvide records of prior chemotherapy course to support approval

    Site of Care and Part B vs Part D Determinations

    Note
    Note
    Note
    Note

    Definitions & Diagnostic Thresholds

    Formulary Index & Coding References

    Products listed (no billing codes presented) — condensed index linesmixed
    N/AIndex and product listing entries in the formulary extract; no billing codes provided in the referenced fragments.
    Formulary identifier referencedmixed
    FID: 26132HealthPartners Part D Formulary identifier referenced in index lines
    Note

    Biosimilar / Preferred Agent Notes

    Note

    Background — Scope and Policy Purpose

    This section summarizes the clinical and diagnostic prerequisites HealthPartners uses to determine Medicare Part D coverage and prior authorization for specialty and other formulary drugs. Key requirements recurring across product entries include confirmation of an FDA‑approved diagnosis (or compendia‑supported indication), documentation of required diagnostic tests or biomarker results where specified (for example, genetic testing or right heart catheterization hemodynamics), evidence of prior trial/failure or contraindication to specified preferred therapies when step therapy is required, prescriber specialty or consultation when indicated, adherence to FDA‑labeled dosing, and avoidance of excluded concurrent therapies or FDA‑labeled contraindications. Failure to meet these specified elements may result in denial of coverage or a determination that the request is not medically necessary.

    Revision History

    2026-03-01policy_effectiveLatest

    HealthPartners Part D prior authorization requirements and coverage criteria became effective (formulary FID: 26132).

    2026-03-01document_publication

    Published comprehensive Medicare Part D prior authorization guidance including product-specific PA criteria, diagnostic requirements, and coverage durations (examples: abiraterone coverage duration six months; many biologics 12 months).